Overexpression of tripartite motif-containing 47 (TRIM47) confers sensitivity to PARP inhibition via ubiquitylation of BRCA1 in triple negative breast cancer cells
Fengen Liu,
Binhui Xie,
Rong Ye,
Yuankang Xie,
Baiyin Zhong,
Jinrong Zhu,
Yao Tang,
Zelong Lin,
Huiru Tang,
Ziqing Wu,
Heping Li
Affiliations
Fengen Liu
Department of General Surgery III, the First Affiliated Hospital of Gannan Medical University
Binhui Xie
Department of General Surgery I, the First Affiliated Hospital of Gannan Medical University
Rong Ye
Department of General Surgery III, the First Affiliated Hospital of Gannan Medical University
Yuankang Xie
Department of General Surgery I, the First Affiliated Hospital of Gannan Medical University
Baiyin Zhong
Department of General Surgery I, the First Affiliated Hospital of Gannan Medical University
Jinrong Zhu
Guangdong Province Key Laboratory for Biotechnology Drug Candidates, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University
Yao Tang
Department of Pathology, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University
Zelong Lin
Department of Pathology, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University
Huiru Tang
Cheerland Watson Precision Medicine Co. Ltd
Ziqing Wu
Department of Pathology, Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University
Heping Li
Department of Medical Oncology, the First Affiliated Hospital of Sun Yat-sen University
Abstract Triple-negative breast cancers (TNBC) frequently harbor defects in DNA double-strand break repair through homologous recombination (HR), such as BRCA1 dysfunction. However, less than 15% of TNBC patients were found to carry BRCA1 mutation, indicating that there are other mechanisms regulating BRCA1-deficient in TNBC. In the current study, we shown that overexpression of TRIM47 correlates with progression and poor prognosis in triple-negative breast cancer. Moreover, we demonstrated that TRIM47 directly interacts with BRCA1 and induces ubiquitin-ligase-mediated proteasome turnover of BRCA1, subsequently leads to a decrease of BRCA1 protein levels in TNBC. Moreover, the downstream gene expression of BRCA1, such as p53, p27, p21 was significantly reduced in the overexpression of TRIM47 cell lines but increased in TRIM47-deleted cells. Functionally, we found that overexpression of TRIM47 in TNBC cells confers an exquisite sensitivity to olaparib, an inhibitor of poly-(ADP-ribose)-polymerase (PARP), but TRIM47 inhibition significantly confers TNBC cells resistance to olaparib both in vitro and in vivo. Furthermore, we showed that overexpression of BRCA1 significant increase the olaparib resistance in TRIM47-overexpression-induced PARP inhibitions sensitivity. Taken together, our results uncover a novel mechanism for BRCA1-deficient in TNBC and targeting TRIM47/BRCA1 axis may be a promising prognostic factor and a valuable therapeutic target for TNBC.